Research programme: antiviral agent - Endevica Bio
Latest Information Update: 31 Mar 2021
Price :
$50 *
At a glance
- Originator Tensive Controls; Unknown
- Developer Endevica Bio; Unknown
- Class Antivirals; Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 30 Mar 2021 Tensive Controls is now called Endevica Bio
- 28 Aug 2020 No recent reports of development identified for research development in Viral-infections in USA (PO)
- 22 Jul 2016 Early research in Viral infections in USA (PO)